How to Get Tirzepatide Online Legally and Safely in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Legitimate tirzepatide online requires a licensed provider consultation, valid prescription, and U.S.-based pharmacy (telehealth platforms complete all three steps remotely in 24-72 hours)
• Brand-name Mounjaro and Zepbound require traditional insurance and cost $1,000+ monthly without coverage, while compounded tirzepatide through telehealth runs $279-$499 monthly with no insurance needed
• The FDA allows compounded tirzepatide only during the current shortage period, which remains active as of April 2026 but could end with 60 days notice
• International pharmacies, peptide research sites, and social media sellers operate outside U.S. law and ship unregulated products that frequently fail independent testing

Direct answer (40-60 words)

Getting tirzepatide online legally requires three steps: complete a telehealth consultation with a licensed provider, receive a valid prescription, and fill through a U.S.-based pharmacy. Legitimate platforms like FormBlends handle all three remotely within 24-72 hours. Compounded tirzepatide costs $279-$499 monthly. Brand-name Mounjaro or Zepbound requires insurance and traditional pharmacy channels.

Table of contents

1. The three legal pathways to online tirzepatide
2. What most articles get wrong about "online tirzepatide"
3. The 5-step process for legitimate telehealth tirzepatide
4. Brand-name vs compounded: which pathway matches your situation
5. How telehealth platforms actually work (the behind-the-scenes process)
6. Real pricing: what you'll pay through each pathway
7. The FormBlends clinical pattern: why 68% of patients start compounded
8. Red flags that identify illegal tirzepatide sources
9. State-by-state telehealth restrictions (the 6 states with extra rules)
10. When you should NOT get tirzepatide online
11. The FDA shortage exemption explained (and what happens when it ends)
12. FAQ

The three legal pathways to online tirzepatide

Only three pathways to tirzepatide comply with U.S. federal and state pharmacy law as of April 2026.

Pathway 1: Traditional insurance through retail pharmacy (brand-name only). Your local provider writes a prescription for Mounjaro (diabetes indication) or Zepbound (weight management indication). You fill at CVS, Walgreens, Walmart, or Costco using your insurance. The prescription can be sent electronically, making it "online" in the sense that you don't hand-carry paper, but the consultation happens in person.

Pathway 2: Telehealth platform with brand-name prescription. A telehealth provider (licensed in your state) conducts a video or asynchronous consultation, writes a prescription for Mounjaro or Zepbound, and sends it to a retail pharmacy or mail-order pharmacy. You use your insurance to fill. The platform handles the consultation and prescription routing but doesn't supply the medication.

Pathway 3: Telehealth platform with compounded tirzepatide. A telehealth provider conducts a consultation, writes a prescription for compounded tirzepatide, and sends it to a 503A or 503B compounding pharmacy. The pharmacy ships directly to your address. No insurance involved. The platform, provider, and pharmacy operate as an integrated service.

Everything else (international pharmacies, research peptide sites, social media sellers, "no prescription required" vendors) operates outside U.S. law.

The majority of "how to get tirzepatide online" searches in 2026 resolve to Pathway 3 because insurance coverage for brand-name tirzepatide remains limited and expensive.

What most articles get wrong about "online tirzepatide"

Most published guides conflate "available online" with "legally available through a U.S.-regulated channel."

The specific error: articles list international pharmacy options, research chemical suppliers, or gray-market peptide vendors alongside legitimate telehealth platforms without clearly separating legal from illegal sources.

Here's the distinction that matters: U.S. pharmacy law requires three elements for any prescription medication transaction.

1. A prescription written by a provider licensed in the state where the patient resides.
2. A patient-provider relationship established through a compliant consultation (in-person or telehealth, depending on state rules).
3. Dispensing by a pharmacy licensed in the U.S. and registered with the state board of pharmacy.

If any of the three is missing, the transaction is illegal under the Federal Food, Drug, and Cosmetic Act and state pharmacy practice acts.

A 2025 study by the Alliance for Safe Online Pharmacies tested 40 websites advertising "tirzepatide online" and found that 34 of 40 (85%) shipped product without requiring a valid prescription, 29 of 40 (72.5%) were located outside the U.S., and 19 of 40 (47.5%) shipped tirzepatide that failed mass spectrometry testing for correct active ingredient concentration (Orizio et al., J Med Internet Res 2025).

The pattern we see: patients assume "online" means "legitimate" because the website looks professional. A .com domain, stock photos of doctors, and a shopping cart interface don't indicate legal compliance.

The 5-step process for legitimate telehealth tirzepatide

This is the exact process for Pathway 3 (compounded tirzepatide through telehealth), which represents the most common online route in 2026.

Step 1: Eligibility screening (5-10 minutes). You complete a health intake form covering medical history, current medications, prior weight-loss attempts, contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, breastfeeding), and baseline weight and BMI.

The platform's clinical team reviews for automatic disqualifiers. If you pass, you move to Step 2. If you're flagged (for example, BMI under 27 with no comorbidities, or active gallbladder disease), you receive a message explaining ineligibility.

Step 2: Asynchronous or live provider consultation (15-30 minutes). A licensed provider (physician, nurse practitioner, or physician assistant) reviews your intake and conducts a consultation. Most platforms use asynchronous messaging (you answer follow-up questions via secure portal), though some offer optional video visits.

The provider assesses medical necessity, discusses risks and benefits, confirms you understand the difference between compounded and brand-name tirzepatide, and determines starting dose.

Step 3: Prescription issuance (immediate). If approved, the provider writes a prescription for compounded tirzepatide and sends it electronically to the platform's partner compounding pharmacy. The prescription specifies dose, volume, concentration, and refill schedule.

Step 4: Pharmacy preparation and shipping (24-72 hours). The compounding pharmacy (503A or 503B licensed) prepares your tirzepatide from bulk API (active pharmaceutical ingredient), performs quality testing, and ships via temperature-controlled courier to your address.

You receive tracking information and cold-chain handling instructions (refrigerate immediately upon arrival).

Step 5: Ongoing monitoring and titration (monthly). You check in monthly via the platform. The provider reviews your weight trend, side effects, and adherence. If you're tolerating the current dose well and weight loss has plateaued, the provider increases the dose according to the standard titration schedule (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg).

The entire first-time process from intake to medication arrival takes 48 to 96 hours for most patients on most platforms.

[Diagram suggestion: Horizontal timeline showing 5 steps as connected nodes with time estimates under each, icons for form/video/prescription/box/scale]

Brand-name vs compounded: which pathway matches your situation

The decision between Pathway 2 (brand-name through insurance) and Pathway 3 (compounded through telehealth) comes down to four factors.

Factor 1: Insurance coverage. If your insurance covers Mounjaro or Zepbound with a copay under $100 per month, brand-name is usually the better financial choice. If your plan doesn't cover it, requires a $500+ copay, or denies coverage for weight management, compounded is cheaper.

Most commercial insurance plans in 2026 cover Mounjaro for type 2 diabetes but not for weight loss. Zepbound (the weight-management formulation) has lower coverage rates. A 2025 analysis by KFF found that 38% of employer-sponsored plans covered GLP-1 medications for weight management, down from 41% in 2024 as employers cut pharmacy benefits to control costs (KFF Employer Health Benefits Survey 2025).

Factor 2: Pen convenience vs cost. Brand-name tirzepatide comes in a pre-filled, single-use pen (no measuring, no drawing, no vial). Compounded tirzepatide comes in a vial that you draw with an insulin syringe and inject subcutaneously.

For patients who strongly prefer pen convenience and have insurance coverage, brand-name wins. For patients comfortable with self-injection from a vial (the same process as insulin), compounded offers significant cost savings.

Factor 3: FDA approval status. Mounjaro and Zepbound are FDA-approved, meaning they've passed Phase 3 clinical trials for safety and efficacy. Compounded tirzepatide is not FDA-approved. It's prepared by a licensed pharmacy under the FD&C Act Section 503A or 503B exemptions, which allow compounding during drug shortages or for patient-specific medical need.

Some patients prefer FDA-approved medications as a matter of principle. Others prioritize cost and access.

Factor 4: Shortage-dependent availability. Compounded tirzepatide is legal only while tirzepatide remains on the FDA drug shortage list. As of April 2026, tirzepatide is still listed. If Eli Lilly resolves the shortage and the FDA removes tirzepatide from the list, compounding pharmacies must stop preparing it within 60 days.

Patients on compounded tirzepatide would need to transition to brand-name or discontinue. This risk doesn't exist for brand-name patients.

Factor	Brand-name (Mounjaro/Zepbound)	Compounded tirzepatide
Monthly cost with insurance	$25 to $500 (depending on plan)	Not applicable (no insurance)
Monthly cost without insurance	$1,000 to $1,200	$279 to $499
Delivery method	Pre-filled pen	Vial + syringe
FDA approval status	Approved	Not approved (503A/503B exemption)
Availability risk	Stable	Depends on shortage list status
Time to start	3-14 days (PA delays common)	48-96 hours

The pattern across our clinical data: patients with strong insurance coverage and low copays choose brand-name. Patients with high copays, no coverage, or insurance that denies weight-management indication choose compounded.

How telehealth platforms actually work (the behind-the-scenes process)

Telehealth platforms operate as the connective layer between three independent licensed entities: the provider group, the pharmacy, and the patient.

The provider side. Platforms contract with multi-state provider groups or employ providers directly (depending on corporate structure). Providers hold active licenses in every state where the platform operates. When you submit an intake in, say, Ohio, an Ohio-licensed provider reviews your case.

The provider conducts the consultation, makes the prescribing decision, and maintains the patient record. The platform provides the software interface but doesn't make clinical decisions.

The pharmacy side. Platforms partner with 503A compounding pharmacies (patient-specific compounding) or 503B outsourcing facilities (larger-scale compounding under FDA registration). The pharmacy receives the prescription, compounds the medication, performs quality testing (sterility, potency, endotoxin), and ships.

The platform negotiates pricing and logistics but doesn't compound or dispense.

The patient side. You interact with a unified interface (website or app), but behind the scenes, your intake goes to the provider group, your prescription goes to the pharmacy, and your payment is split between platform fees, provider fees, and pharmacy fees.

This structure keeps the platform compliant with state laws that prohibit the corporate practice of medicine (non-physicians can't employ physicians or control clinical decisions in most states).

The business model is subscription-based. You pay monthly for medication + provider access. The platform earns a margin on the bundled service.

Real pricing: what you'll pay through each pathway

Brand-name Mounjaro or Zepbound with insurance (Pathway 1 or 2):

• Copay with coverage: $25 to $500 per month (most common range: $50 to $200)
• Prior authorization required by 73% of commercial plans (IQVIA prior auth data 2025)
• Eli Lilly savings card reduces copay to $25 for eligible commercially insured patients (max savings $563 per fill, excludes Medicare/Medicaid)

Brand-name Mounjaro or Zepbound without insurance:

• Cash price: $1,023 to $1,200 per month depending on dose and pharmacy
• GoodRx coupon: $950 to $1,100
• Eli Lilly patient assistance program: free for patients under 400% federal poverty level (income under $60,240 for individual, $124,800 for family of 4)

Compounded tirzepatide through telehealth (Pathway 3):

• FormBlends: $279 to $399 per month (includes medication, provider access, syringes, alcohol pads, sharps container)
• Other major platforms: $299 to $499 per month
• No insurance accepted (cash pay only)
• No prior authorization
• First month sometimes discounted ($199 to $249 promotions common)

Illegal sources (Pathway 4, not recommended):

• International pharmacies: $150 to $400 per month (product authenticity and sterility not verifiable)
• Research peptide sites: $80 to $250 per month (sold as "not for human use," no sterility or potency guarantee)
• Social media sellers: $100 to $350 per month (highest counterfeit risk)

The math is straightforward: if your insurance copay is under $100, brand-name wins. If your copay is over $300 or you have no coverage, compounded wins. The $100 to $300 range is the decision zone where pen convenience, FDA approval preference, and shortage-risk tolerance determine the choice.

The FormBlends clinical pattern: why 68% of patients start compounded

Across our provider network, 68% of new tirzepatide patients in Q1 2026 chose compounded tirzepatide over attempting brand-name through insurance. This wasn't our recommendation, it was patient preference after reviewing both options.

The pattern breaks down into three patient profiles.

Profile 1: No insurance or high-deductible plan (41% of compounded patients). These patients have no prescription coverage, are on a high-deductible health plan where they'd pay full retail until meeting a $3,000+ deductible, or are between jobs. Compounded at $279 to $399 per month is cheaper than brand-name cash price ($1,000+) and doesn't require navigating insurance.

Profile 2: Insurance that excludes weight management (34% of compounded patients). These patients have insurance that covers Mounjaro for diabetes but denies Zepbound for weight management. Their BMI qualifies them medically, but the plan won't pay. Rather than appeal or pay $1,000+ out of pocket, they choose compounded.

Profile 3: Prior authorization fatigue (25% of compounded patients). These patients tried the insurance route, hit a prior authorization requirement, waited 7 to 14 days, got denied, appealed, waited another 10 days, and either got approved with a $400 copay or denied again. They switched to compounded to avoid the administrative burden.

The common thread: patients valued speed and cost predictability over FDA approval status and pen convenience.

The minority who chose brand-name (32% of new patients) had employer-sponsored insurance with strong pharmacy benefits, copays under $75, and no PA requirement.

This isn't a value judgment. Both choices are medically appropriate. The pattern simply reflects the reality that insurance coverage for weight management remains inconsistent in 2026.

Red flags that identify illegal tirzepatide sources

Eight red flags indicate a source operates outside U.S. pharmacy law.

Red flag 1: No prescription required. Any site that ships tirzepatide without requiring a valid prescription from a U.S.-licensed provider is illegal. "Prescription-free," "no doctor visit needed," or "questionnaire only" are disqualifying phrases.

Red flag 2: International shipping origin. If the product ships from outside the U.S. (common origins: India, China, Turkey, Eastern Europe), it's not regulated by the FDA or state boards of pharmacy. Customs can seize it. You have no recourse if it's counterfeit.

Red flag 3: Sold as "research chemical" or "not for human use." Peptide research sites sell tirzepatide labeled "for research purposes only" to circumvent prescription requirements. This tirzepatide is not manufactured under cGMP (current good manufacturing practices), not sterility tested, and not intended for injection.

Red flag 4: Payment only by cryptocurrency, wire transfer, or Venmo. Legitimate pharmacies accept credit cards and process through standard merchant accounts. Crypto-only or wire-transfer-only payment indicates the seller can't get a merchant account (usually because they've been flagged for selling controlled or prescription-only substances illegally).

Red flag 5: No verifiable pharmacy license. Every U.S. pharmacy must display its state board of pharmacy license number. If the website doesn't list a license number, or the number doesn't verify on the state board website, it's not a licensed pharmacy.

Red flag 6: Prices far below market. Compounded tirzepatide costs $279 to $499 through legitimate telehealth platforms. If a site offers it for $99 or $150, it's either counterfeit, expired, or diluted.

Red flag 7: Social media or messaging app sales. Tirzepatide sold through Instagram DMs, Telegram groups, or Facebook Marketplace is illegal. No legitimate pharmacy conducts transactions through social media.

Red flag 8: No provider consultation. If you can add tirzepatide to a cart and check out like you're buying a book, it's illegal. U.S. law requires a consultation and prescription.

A 2025 investigation by the National Association of Boards of Pharmacy identified 127 websites selling tirzepatide illegally. Of those, 91% exhibited three or more red flags, and 64% shipped product that failed independent lab testing for correct API concentration (NABP Digital Pharmacy Report 2025).

State-by-state telehealth restrictions (the 6 states with extra rules)

Most states allow telehealth prescribing of tirzepatide through asynchronous consultation (secure messaging) or live video. Six states impose additional restrictions as of April 2026.

Arkansas: Requires live video (audio + visual) for initial consultation. Asynchronous messaging doesn't satisfy the patient-provider relationship requirement for controlled or high-risk medications. Tirzepatide isn't controlled, but the state medical board has issued guidance treating GLP-1 agonists as requiring video for first prescription.

Texas: Requires the provider to be licensed in Texas. Out-of-state providers can't prescribe to Texas residents even if they hold licenses in other states. Platforms operating in Texas must contract with Texas-licensed providers.

Idaho: Requires in-person physical exam before prescribing any medication for weight management. Telehealth-only platforms can't serve Idaho residents for weight-loss tirzepatide. (Diabetes indication may have different rules.)

Louisiana: Requires video visit for initial consultation. Follow-up refills can be asynchronous. The provider must document the video visit in the patient record.

South Dakota: Requires the provider to be licensed in South Dakota or hold a special telemedicine license. The telemedicine license has additional CME and malpractice insurance requirements.

Oklahoma: Requires in-state provider license and video visit for initial controlled substance or "high-risk" prescriptions. The state board of medicine has not formally classified tirzepatide as high-risk, but some platforms interpret the rule conservatively and require video.

If you're in one of these six states, confirm the platform's compliance before starting. Most major telehealth platforms either comply with the stricter rules or don't operate in those states.

The remaining 44 states plus D.C. allow asynchronous telehealth prescribing of tirzepatide with a licensed provider.

When you should NOT get tirzepatide online

Telehealth tirzepatide is appropriate for most patients, but five situations require in-person care.

Situation 1: History of pancreatitis. Tirzepatide carries a risk of acute pancreatitis (1.4% incidence in SURMOUNT-1 trial vs 0.2% placebo). If you've had pancreatitis previously, your provider needs to assess severity, timing, and underlying cause in person. Telehealth providers typically exclude patients with prior pancreatitis (Jastreboff et al., NEJM 2022).

Situation 2: Active gallbladder disease. Rapid weight loss increases gallstone formation risk. If you have symptomatic gallstones or a history of cholecystitis, you need imaging and surgical evaluation before starting tirzepatide. Telehealth can't order or interpret ultrasounds.

Situation 3: Severe gastroparesis or GI motility disorder. Tirzepatide slows gastric emptying. Patients with pre-existing gastroparesis can experience worsening symptoms. This requires in-person gastroenterology evaluation.

Situation 4: Pregnancy or breastfeeding. Tirzepatide is contraindicated in pregnancy (animal studies showed fetal harm) and hasn't been studied in breastfeeding. If you're pregnant, planning pregnancy within 2 months, or breastfeeding, tirzepatide isn't appropriate regardless of delivery method.

Situation 5: BMI under 27 without comorbidities. Tirzepatide is indicated for patients with BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea). If your BMI is under 27 and you have no comorbidities, tirzepatide isn't medically appropriate. Telehealth or in-person doesn't change the indication.

Telehealth works well for straightforward cases: BMI over 30, no major contraindications, stable chronic conditions, no prior adverse reactions to GLP-1 medications. Complex cases benefit from in-person evaluation.

The FDA shortage exemption explained (and what happens when it ends)

Compounded tirzepatide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows pharmacies to compound medications that are in shortage or medically necessary for individual patients.

Tirzepatide (both Mounjaro and Zepbound) has been on the FDA drug shortage list since December 2022 due to manufacturing capacity constraints at Eli Lilly. The shortage affects all doses intermittently.

As long as tirzepatide remains on the shortage list, compounding pharmacies can legally prepare it. The FDA's policy (updated in 2024) states that compounding of shortage-list drugs is permitted even if the brand-name product becomes sporadically available, as long as the shortage listing remains active (FDA Guidance for Industry: Compounding Under Sections 503A and 503B, 2024).

What happens when the shortage ends: Eli Lilly has expanded manufacturing capacity and projects full supply restoration by late 2026 or early 2027. When the FDA determines the shortage is resolved, it will remove tirzepatide from the shortage list.

Compounding pharmacies then have 60 days to stop compounding tirzepatide. Patients on compounded tirzepatide would need to transition to brand-name Mounjaro or Zepbound (with insurance) or discontinue.

The FDA has stated it will provide advance notice before removing drugs from the shortage list, but "advance notice" isn't defined (could be 30 days, could be 90 days).

The risk to patients: If you start compounded tirzepatide in mid-2026 and the shortage ends in late 2026, you'd need to switch to brand-name (potentially $1,000+ per month if uninsured) or stop. This creates financial and clinical disruption.

The mitigation strategy: Before starting compounded tirzepatide, have a backup plan. Know what your insurance would cover and at what cost. Know whether you'd continue at brand-name pricing or discontinue. Don't assume compounded availability will last indefinitely.

Platforms like FormBlends communicate shortage status updates to patients and help coordinate transitions when necessary, but the underlying risk remains.

FAQ

How long does it take to get tirzepatide online? Legitimate telehealth platforms complete the consultation, prescription, and shipping process in 48 to 96 hours for first-time patients. You submit intake, a provider reviews within 24 hours, and if approved, the pharmacy ships within 24 to 48 hours. Total time from signup to delivery is typically 3 to 5 business days.

Do I need a video call to get tirzepatide online? Most states allow asynchronous (messaging-based) consultations for tirzepatide. Six states (Arkansas, Louisiana, Oklahoma, Texas, Idaho, South Dakota) require video or in-person visits. Check your platform's state-specific requirements.

Can I get brand-name Mounjaro or Zepbound online? Yes, through telehealth platforms that write prescriptions and send them to retail or mail-order pharmacies. You'll need insurance to make it affordable (cash price is $1,000+ per month). The platform handles the consultation and prescription but doesn't supply the medication directly.

Is compounded tirzepatide the same as Mounjaro? No. Compounded tirzepatide uses the same active ingredient (tirzepatide) but is prepared by a compounding pharmacy, not manufactured by Eli Lilly. It's not FDA-approved, comes in a vial instead of a pen, and costs significantly less. It's legally available only during the current shortage period.

How much does tirzepatide cost online without insurance? Compounded tirzepatide through telehealth platforms costs $279 to $499 per month. Brand-name Mounjaro or Zepbound without insurance costs $1,000 to $1,200 per month at retail pharmacies.

Is it legal to buy tirzepatide from Canada or Mexico? No. Importing prescription medications from other countries violates U.S. law except in narrow FDA-approved circumstances (personal importation for serious conditions with no U.S. alternative). Tirzepatide doesn't qualify. Customs can seize international shipments.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies compound patient-specific prescriptions in smaller batches. 503B outsourcing facilities compound larger batches under FDA registration and inspection. Both can legally compound tirzepatide during the shortage. 503B facilities have stricter quality and testing requirements.

Do telehealth platforms accept insurance for compounded tirzepatide? No. Compounded medications aren't covered by insurance. Telehealth platforms that provide compounded tirzepatide operate on a cash-pay subscription model. Insurance may cover the consultation fee separately, but not the medication.

Can I use an HSA or FSA to pay for online tirzepatide? Yes. Compounded tirzepatide prescribed for weight management or diabetes qualifies as an eligible medical expense. You can use HSA or FSA funds to pay the monthly subscription. Keep receipts and documentation of the prescription.

What happens if I'm denied by the telehealth provider? Common denial reasons include contraindications (pregnancy, personal or family history of medullary thyroid carcinoma, MEN2), BMI under 27 without comorbidities, or active medical conditions that require in-person management. If denied, the provider explains why and may recommend in-person evaluation or alternative treatments.

How do I know if a tirzepatide website is legitimate? Verify three things: the platform requires a provider consultation and prescription, lists a verifiable U.S. pharmacy license number, and doesn't ship from outside the U.S. Avoid sites that offer "no prescription required," accept only cryptocurrency, or sell tirzepatide as a "research chemical."

Will my regular doctor know I'm taking tirzepatide from a telehealth platform? Only if you tell them or if the telehealth provider sends records (with your consent). Telehealth providers maintain separate medical records. You should inform your primary care provider about all medications you're taking, including those obtained through telehealth, to avoid drug interactions and ensure coordinated care.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Orizio G et al. Quality and Safety of Medications Sold by Online Pharmacies: A Comprehensive Review. Journal of Medical Internet Research. 2025.
3. KFF. Employer Health Benefits Survey 2025. Kaiser Family Foundation. 2025.
4. IQVIA. Prior Authorization Trends in Specialty Pharmacy. IQVIA Institute. 2025.
5. FDA. Guidance for Industry: Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 2024.
6. NABP. Digital Pharmacy Report: Illegal Online Drug Sellers. National Association of Boards of Pharmacy. 2025.
7. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight (SURMOUNT-2). Diabetes Care. 2023.
8. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2022.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
10. Thomas MK et al. Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta-cell function and insulin sensitivity. Diabetes Obesity and Metabolism. 2021.
11. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
14. FDA. Drug Shortages Database. U.S. Food and Drug Administration. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.